Table 3.
The effect of treatment interruption and other factors on unsuccessful treatment outcome in MDR-TB patients.
| Variable | Treatment outcome | Unadjusted model | Adjusted model | ||||
|---|---|---|---|---|---|---|---|
| Successful, n (%) | Unsuccessful, n (%) | URR(95% CI) | P-value | ARR(95%CI) | P-Value | ||
| Treatment interruption status | Never interrupted | 158 (77.8) | 45 (22.2) | 1.00 | 1.00 | ||
| At least one day interrupted | 119 (58.3) | 85 (41.7) | 1.9 (1.4–2.5) | < 0.001* | 1.9 (1.4–2.6) | < 0.001* | |
| Sex | Male | 156(68.1) | 73 (31.9) | 1.00 | |||
| Female | 121 (68.0) | 57(32.0) | 1.0 (0.75–1.3) | 0.975 | |||
| Age in year | 1.1 (0.99–1.1) | 0.091 | 1.0 (0.99–1.1) | 0.203 | |||
| Resistance type | Rifampin resistant/Isoniazid susceptibility unknown | 194 (66.2) | 99 (33.8) | 1.00 | |||
| Multidrug resistant | 83 (72.8) | 31 (27.2) | 0.80 (0.57–1.1) | 0.212 | |||
| Anatomical site of TB | Extra-pulmonary | 9 (47.4) | 10 (52.60 | 1.00 | 1.00 | ||
| Pulmonary | 268 (69.10 | 120 (30.9) | 0.59 (0.37–0.92) | 0.021 | 0.64 (0.40–1.04) | 0.072 | |
| Previous treatment history | New | 36 (60.0) | 24 (40.0) | 1.00 | 1.00 | ||
| Previously treated | 241 (69.5) | 106 (30.5) | 0.76 (0.54–1.1) | 0.130 | 0.83 (0.59–1.2) | 0.273 | |
| Previous history of SLDs exposure | No | 263 (68.0) | 124 (32.0) | 1.00 | |||
| Yes | 11 (64.7) | 6 (35.3) | 1.1 (0.57–2.1) | 0.774 | |||
| Reasons for entering to MDR-TB treatment | Bacteriologically diagnosed | 263 ()68.7 | 120 (31.3) | 1.00 | |||
| Clinically diagnosed | 14 (58.3) | 10 (41.7) | 1.3 (0.81–2.2) | 0.261 | |||
| HIV sero-status | Non-reactive | 225 (71.0) | 92 (29.0) | 1.00 | 1.00 | ||
| Sero-reactive | 48 (57.1) | 36 (42.9) | 1.5 (1.1–2.0) | 0.011* | 1.4 (1.1–1.9) | 0.016* | |
| ART status | Not applicable | 225 ()71.0 | 92 (29.0) | 1.00 | |||
| ART started | 42 (57.5) | 31 (42.5) | 1.5 (1.1–2.0) | 0.019* | |||
| Anaemia | Normal | 155 (73.8) | 55 (26.2) | 1.00 | 1.00 | ||
| Any grade of anaemia present | 122 (61.9) | 75 (38.1) | 1.4 (1.1–1.9) | 0.011* | 1.3 (1.03–1.8) | 0.049* | |
MDR-multidrug resistant, TB-tuberculosis, SLDs- second line drugs, URR-unadjusted risk ratio, ARR-Adjusted risk ratio, CI-Confidence interval, HIV-Human immunodeficiency virus, ART-antiretroviral therapy, *-statistically significant variable at p-value 0.05.